Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL31213259 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL28049255 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL1457856 | 1.00 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Lithium Ion SCHEMBL1458069 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL28027050 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL16029799 | 0.98 | LMNA (0.95) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL19973172 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Lithium Ion SCHEMBL1458070 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL16030009 | 0.98 | LMNA (0.87) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Gluconic Acid SCHEMBL23567041 | 0.95 | LMNA (0.91) | LMNAPDE4AL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551456-B2 | Methods to improve health and wellbeing in ruminants | NUTRECO IP ASSETS B.V. (NL) | 2026-02-17 | — | — | US | claimed |
| US-12544361-B2 | Composition comprising at least one oxazoline for inhibiting the growth of Malassezia yeasts involved in cradle cap, in particular | LABORATOIRES EXPANSCIENCE (FR) | 2026-02-10 | — | — | US | claimed |
| US-20250345362-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS PHARMA (BE) | 2025-11-13 | — | — | US | claimed |
| US-20250228889-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | LUENINGHOENER CATHERINE (US) | 2025-07-17 | — | — | US | claimed |
| CN-119725490-A | Lithium supplementing agent, preparation method thereof, positive electrode plate and secondary battery | 湖北万润新能源科技股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025064524-A1 | CONTAMINANT PRECIPITATION COMPOSITIONS AND METHODS OF USE | LOCUS SOLUTIONS IPCO, LLC (US) | 2025-03-27 | — | — | WO | claimed |
| EP-4525889-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS Pharma (BE) | 2025-03-26 | — | — | EP | claimed |
| CN-119176584-B | Preparation method of positive electrode material | 深圳先进技术研究院 | 2025-02-18 | — | — | CN | claimed |
| CN-119361657-A | Lithium ion positive electrode material, preparation method thereof and lithium ion battery | 厦门厦钨新能源材料股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119317438-A | Polyion complexes for preventing or treating inflammation | 伊尼奥斯制药公司 | 2025-01-14 | — | — | CN | claimed |
| US-6533398-B2 | Method of reducing kogation on heater of ink-jet recording head, ink-jet recording process, ink-jet recording apparatus, recording unit, and method for lengthening the life of recording head | CANON KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | claimed |
| US-20020119174-A1 | Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | claimed |
| US-20020113842-A1 | Method of reducing kogation on heater of ink-jet recording head, ink-jet recording process, ink-jet recording apparatus, recording unit, and method for lengthening the life of recording head | CANON KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | US | claimed |
| WO-2002007700-A2 | COMPOSITIONS USEFUL FOR REGULATING HAIR GROWTH CONTAINING METAL COMPLEXES OF OXIDIZED CARBOHYDRATES | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1029680-A2 | Method of reducing kogation on heater of ink-jet recording head, ink-jet recording process, ink-jet recording apparatus, recording unit, and method for lengthening the life of recording head | CANON KABUSHIKI KAISHA (JP) | 2000-08-23 | — | — | EP | claimed |
| EP-0730463-B1 | USE OF LITHIUM COMPOUNDS IN THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE | LEHMANN KARLA (DE) | 2000-02-02 | — | — | EP | claimed |
| EP-0714276-B1 | COMPOSITION AGAINST HAIR LOSS AND BRITTLE NAILS | OURY JEAN PIERRE MAURICE (FR) | 1998-11-25 | — | — | EP | claimed |
| EP-0234733-B1 | PHARMACEUTICAL COMPOSITIONS | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1991-11-13 | — | — | EP | claimed |
| US-4810497-A | Pharmaceutical compositions | EFAMOL LIMITED (GB) | 1989-03-07 | — | — | US | claimed |
| EP-0234733-A1 | Pharmaceutical compositions | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1987-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119174-A1 | Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates | OSTC, LPO, UGCG | LMNA 3933/4885PDE4A 4186/4885L3MBTL1 4036/4885 |
| US-12544361-B2 | Composition comprising at least one oxazoline for inhibiting the growth of Malassezia yeasts involved in cradle cap, in particular | HSD17B12, CYP51A1, OXGR1 | LMNA 4849/4885PDE4A 3575/4885L3MBTL1 3288/4885 |
| US-12551456-B2 | Methods to improve health and wellbeing in ruminants | SLC30A6, SLC2A9, SLC39A7 | LMNA 1539/4885PDE4A 4591/4885L3MBTL1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.